Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Urological Cancer Therapeutics Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Xofigo (radium Ra 223 dichloride)
      • 1.3.3 Jevtana (cabazitaxel)
      • 1.3.4 Inlyta (axitinib)
      • 1.3.5 Votrient (pazopanib hydrochloride)
      • 1.3.6 Sutent (sunitinib malate)
      • 1.3.7 Zytiga (abiraterone acetate)
      • 1.3.8 Xtandi (enzalutamide)
      • 1.3.9 Opdivo (nivolumab)
      • 1.3.10 Provenge (sipuleucel-T)
    • 1.4 Market Segment by Application
      • 1.4.1 Global Urological Cancer Therapeutics Drugs Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Medical Research Laboratory
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Urological Cancer Therapeutics Drugs Market Size
      • 2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2014-2025
      • 2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2014-2025
    • 2.2 Urological Cancer Therapeutics Drugs Growth Rate by Regions
      • 2.2.1 Global Urological Cancer Therapeutics Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Urological Cancer Therapeutics Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
      • 3.1.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Urological Cancer Therapeutics Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Urological Cancer Therapeutics Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
    • 3.6 Key Manufacturers Urological Cancer Therapeutics Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Xofigo (radium Ra 223 dichloride) Sales and Revenue (2014-2019)
      • 4.1.2 Jevtana (cabazitaxel) Sales and Revenue (2014-2019)
      • 4.1.3 Inlyta (axitinib) Sales and Revenue (2014-2019)
      • 4.1.4 Votrient (pazopanib hydrochloride) Sales and Revenue (2014-2019)
      • 4.1.5 Sutent (sunitinib malate) Sales and Revenue (2014-2019)
      • 4.1.6 Zytiga (abiraterone acetate) Sales and Revenue (2014-2019)
      • 4.1.7 Xtandi (enzalutamide) Sales and Revenue (2014-2019)
      • 4.1.8 Opdivo (nivolumab) Sales and Revenue (2014-2019)
      • 4.1.9 Provenge (sipuleucel-T) Sales and Revenue (2014-2019)
    • 4.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type
    • 4.3 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type
    • 4.4 Urological Cancer Therapeutics Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Urological Cancer Therapeutics Drugs Sales by Application

    6 United States

    • 6.1 United States Urological Cancer Therapeutics Drugs Breakdown Data by Company
    • 6.2 United States Urological Cancer Therapeutics Drugs Breakdown Data by Type
    • 6.3 United States Urological Cancer Therapeutics Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Urological Cancer Therapeutics Drugs Breakdown Data by Company
    • 7.2 European Union Urological Cancer Therapeutics Drugs Breakdown Data by Type
    • 7.3 European Union Urological Cancer Therapeutics Drugs Breakdown Data by Application

    8 China

    • 8.1 China Urological Cancer Therapeutics Drugs Breakdown Data by Company
    • 8.2 China Urological Cancer Therapeutics Drugs Breakdown Data by Type
    • 8.3 China Urological Cancer Therapeutics Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Urological Cancer Therapeutics Drugs Breakdown Data by Company
    • 9.2 Rest of World Urological Cancer Therapeutics Drugs Breakdown Data by Type
    • 9.3 Rest of World Urological Cancer Therapeutics Drugs Breakdown Data by Application
    • 9.4 Rest of World Urological Cancer Therapeutics Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Urological Cancer Therapeutics Drugs Sales by Countries
      • 9.4.2 Rest of World Urological Cancer Therapeutics Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Novartis
      • 10.1.1 Novartis Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.1.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.1.5 Novartis Recent Development
    • 10.2 Pfizer
      • 10.2.1 Pfizer Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.2.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.2.5 Pfizer Recent Development
    • 10.3 Johnson & Johnson
      • 10.3.1 Johnson & Johnson Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.3.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.3.5 Johnson & Johnson Recent Development
    • 10.4 AstraZeneca
      • 10.4.1 AstraZeneca Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.4.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.4.5 AstraZeneca Recent Development
    • 10.5 Astellas
      • 10.5.1 Astellas Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.5.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.5.5 Astellas Recent Development
    • 10.6 Bristol-Myers Squibb
      • 10.6.1 Bristol-Myers Squibb Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.6.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.6.5 Bristol-Myers Squibb Recent Development
    • 10.7 Abbott Laboratories
      • 10.7.1 Abbott Laboratories Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.7.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.7.5 Abbott Laboratories Recent Development
    • 10.8 Celgene Corporation
      • 10.8.1 Celgene Corporation Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.8.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.8.5 Celgene Corporation Recent Development
    • 10.9 Dendreon Corporation
      • 10.9.1 Dendreon Corporation Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.9.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.9.5 Dendreon Corporation Recent Development
    • 10.10 Ferring Pharmaceuticals
      • 10.10.1 Ferring Pharmaceuticals Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Urological Cancer Therapeutics Drugs
      • 10.10.4 Urological Cancer Therapeutics Drugs Product Introduction
      • 10.10.5 Ferring Pharmaceuticals Recent Development
    • 10.11 GlaxoSmithKline plc
    • 10.12 Indevus Pharmaceuticals Inc
    • 10.13 Ipsen
    • 10.14 Roche Healthcare
    • 10.15 Sanofi S.A.

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Urological Cancer Therapeutics Drugs Sales Channels
      • 11.2.2 Urological Cancer Therapeutics Drugs Distributors
    • 11.3 Urological Cancer Therapeutics Drugs Customers

    12 Market Forecast

    • 12.1 Global Urological Cancer Therapeutics Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type
    • 12.3 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application
    • 12.4 Urological Cancer Therapeutics Drugs Forecast by Regions
      • 12.4.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Urological Cancer Therapeutics Drugs is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Urological Cancer Therapeutics Drugs.

      This report studies the global market size of Urological Cancer Therapeutics Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Urological Cancer Therapeutics Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Novartis
      Pfizer
      Johnson & Johnson
      AstraZeneca
      Astellas
      Bristol-Myers Squibb
      Abbott Laboratories
      Celgene Corporation
      Dendreon Corporation
      Ferring Pharmaceuticals
      GlaxoSmithKline plc
      Indevus Pharmaceuticals Inc
      Ipsen
      Roche Healthcare
      Sanofi S.A.

      Market Segment by Product Type
      Xofigo (radium Ra 223 dichloride)
      Jevtana (cabazitaxel)
      Inlyta (axitinib)
      Votrient (pazopanib hydrochloride)
      Sutent (sunitinib malate)
      Zytiga (abiraterone acetate)
      Xtandi (enzalutamide)
      Opdivo (nivolumab)
      Provenge (sipuleucel-T)

      Market Segment by Application
      Hospital
      Medical Research Laboratory
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Urological Cancer Therapeutics Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Urological Cancer Therapeutics Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Urological Cancer Therapeutics Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now